10 Best Ben Graham Heatmap Picks for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In the current market environment, technology and healthcare sectors show strong revenue growth and high ROIC, while select picks offer compelling intrinsic value opportunities based on ValueSense metrics. These top 10 stock picks were selected using ValueSense's proprietary screening methodology, focusing on Quality rating, intrinsic value comparisons, robust Free Cash Flow, and growth indicators like revenue growth and ROIC. Stocks highlight undervalued positions across tech leaders like NVDA and MU, pharma giants such as LLY and ABBV, and stable names like PM, prioritizing those with high margins and positive 1Y returns for diversified stock watchlist potential.
Featured Stock Analysis
Stock #1: NVIDIA Corporation (NVDA)
| Metric | Value |
|---|---|
| Market Cap | $4,608.1B |
| Quality Rating | 8.1 |
| Intrinsic Value | $75.6 |
| 1Y Return | 36.6% |
| Revenue | $187.1B |
| Free Cash Flow | $77.3B |
| Revenue Growth | 65.2% |
| FCF margin | 41.3% |
| Gross margin | 70.1% |
| ROIC | 161.5% |
| Total Debt to Equity | 9.1% |
Investment Thesis
NVIDIA Corporation (NVDA) stands out with a Quality rating of 8.1 and massive scale, boasting a Market Cap of $4,608.1B, Revenue of $187.1B, and exceptional Free Cash Flow of $77.3B. The company's Revenue growth of 65.2% and sky-high ROIC of 161.5% underscore its dominance in high-margin tech, supported by a stellar Gross margin of 70.1% and FCF margin of 41.3%. Despite a strong 1Y Return of 36.6%, the Intrinsic value of $75.6 suggests potential undervaluation for long-term holders analyzing fundamental strength. Low Total Debt to Equity at 9.1% adds financial stability, making NVDA a core pick for growth-oriented value analysis.
Key Catalysts
- Explosive Revenue growth at 65.2%, driving scalability in AI and computing sectors
- Industry-leading ROIC of 161.5%, indicating superior capital efficiency
- Robust Free Cash Flow of $77.3B with 41.3% margins for reinvestment
- High Gross margin of 70.1%, reflecting pricing power and cost control
Risk Factors
- High Market Cap exposure to market volatility in tech rallies
- Dependence on sustained demand for growth at current scale
- Potential margin pressure from competition in semiconductors
Stock #2: Eli Lilly and Company (LLY)
| Metric | Value |
|---|---|
| Market Cap | $958.1B |
| Quality Rating | 7.9 |
| Intrinsic Value | $279.3 |
| 1Y Return | 39.1% |
| Revenue | $59.4B |
| Free Cash Flow | $9,020.7M |
| Revenue Growth | 45.4% |
| FCF margin | 15.2% |
| Gross margin | 83.0% |
| ROIC | 36.0% |
| Total Debt to Equity | 178.2% |
Investment Thesis
Eli Lilly and Company (LLY), with a Market Cap of $958.1B and Quality rating of 7.9, delivers strong healthcare fundamentals including Revenue of $59.4B and Free Cash Flow of $9,020.7M. Impressive Revenue growth of 45.4% pairs with a Gross margin of 83.0% and ROIC of 36.0%, while 1Y Return hit 39.1%. The Intrinsic value of $279.3 positions it as an undervalued growth name in pharmaceuticals, though Total Debt to Equity at 178.2% warrants monitoring. FCF margin of 15.2% supports ongoing innovation in this sector.
Key Catalysts
- Rapid Revenue growth of 45.4%, fueled by drug pipeline expansions
- Elite Gross margin of 83.0%, highlighting profitability in healthcare
- Solid ROIC at 36.0% for efficient R&D capital deployment
- Positive 1Y Return of 39.1%, reflecting market recognition
Risk Factors
- Elevated Total Debt to Equity of 178.2%, increasing leverage risk
- Regulatory hurdles common in pharma development
- FCF margin at 15.2% trails some peers amid growth investments
Stock #3: Oracle Corporation (ORCL)
| Metric | Value |
|---|---|
| Market Cap | $557.8B |
| Quality Rating | 6.1 |
| Intrinsic Value | $168.0 |
| 1Y Return | 18.2% |
| Revenue | $61.0B |
| Free Cash Flow | ($13.2B) |
| Revenue Growth | 11.1% |
| FCF margin | (21.6%) |
| Gross margin | 78.0% |
| ROIC | 13.1% |
| Total Debt to Equity | 408.4% |
Investment Thesis
Oracle Corporation (ORCL) features a Market Cap of $557.8B and Quality rating of 6.1, with Revenue at $61.0B but negative Free Cash Flow of $13.2B and FCF margin of 21.6%. Steady Revenue growth of 11.1%, Gross margin of 78.0%, and ROIC of 13.1% provide a base, alongside 1Y Return of 18.2%. Intrinsic value of $168.0 indicates value potential in cloud tech, despite high Total Debt to Equity of 408.4%, offering analysis for turnaround-focused investors.
Key Catalysts
- Consistent Revenue growth of 11.1% in enterprise software
- Strong Gross margin of 78.0% for operational leverage
- ROIC of 13.1% supporting long-term tech infrastructure plays
- Improving 1Y Return at 18.2% amid cloud transitions
Risk Factors
- Negative Free Cash Flow of $13.2B, signaling cash burn concerns
- Very high Total Debt to Equity at 408.4%
- Lower Quality rating of 6.1 relative to tech peers
Stock #4: AbbVie Inc. (ABBV)
| Metric | Value |
|---|---|
| Market Cap | $407.0B |
| Quality Rating | 6.4 |
| Intrinsic Value | $301.8 |
| 1Y Return | 29.0% |
| Revenue | $59.6B |
| Free Cash Flow | $20.6B |
| Revenue Growth | 7.4% |
| FCF margin | 34.5% |
| Gross margin | 76.2% |
| ROIC | 12.0% |
| Total Debt to Equity | (2,645.0%) |
Investment Thesis
AbbVie Inc. (ABBV) holds a Market Cap of $407.0B and Quality rating of 6.4, generating Revenue of $59.6B and strong Free Cash Flow of $20.6B with FCF margin of 34.5%. Modest Revenue growth of 7.4% complements Gross margin of 76.2% and ROIC of 12.0%, with 1Y Return at 29.0%. Intrinsic value of $301.8 suggests undervaluation in biotech, offset by extreme Total Debt to Equity of 2,645.0%.
Key Catalysts
- High FCF margin of 34.5% and $20.6B cash generation
- Reliable Gross margin of 76.2% in stable pharma operations
- 1Y Return of 29.0% from dividend appeal
- Intrinsic value upside at $301.8
Risk Factors
- Negative Total Debt to Equity of 2,645.0%, heavy leverage
- Slower Revenue growth at 7.4%
- Patent cliffs in biopharma pipeline
Stock #5: Micron Technology, Inc. (MU)
| Metric | Value |
|---|---|
| Market Cap | $345.8B |
| Quality Rating | 8.2 |
| Intrinsic Value | $435.3 |
| 1Y Return | 261.0% |
| Revenue | $42.3B |
| Free Cash Flow | $17.3B |
| Revenue Growth | 45.4% |
| FCF margin | 40.9% |
| Gross margin | 45.3% |
| ROIC | 25.4% |
| Total Debt to Equity | 20.2% |
Investment Thesis
Micron Technology, Inc. (MU) excels with Quality rating 8.2, Market Cap $345.8B, Revenue $42.3B, and Free Cash Flow $17.3B (FCF margin 40.9%). Stellar Revenue growth 45.4%, ROIC 25.4%, and 1Y Return 261.0% highlight memory chip strength, with Gross margin 45.3% and low Total Debt to Equity 20.2%. Intrinsic value $435.3 points to significant value in semiconductors.
Key Catalysts
- Exceptional 1Y Return of 261.0% from demand surge
- Revenue growth 45.4% matching sector boom
- Strong FCF margin 40.9% and ROIC 25.4%
- Low Total Debt to Equity 20.2% for balance sheet health
Risk Factors
- Cyclical semiconductor industry volatility
- Gross margin 45.3% below some tech peers
- High growth may face normalization
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: Cisco Systems, Inc. (CSCO)
| Metric | Value |
|---|---|
| Market Cap | $299.5B |
| Quality Rating | 6.6 |
| Intrinsic Value | $84.3 |
| 1Y Return | 29.5% |
| Revenue | $57.7B |
| Free Cash Flow | $13.1B |
| Revenue Growth | 8.9% |
| FCF margin | 22.6% |
| Gross margin | 65.0% |
| ROIC | 13.7% |
| Total Debt to Equity | 59.9% |
Investment Thesis
Cisco Systems, Inc. (CSCO) offers Market Cap $299.5B, Quality rating 6.6, Revenue $57.7B, and Free Cash Flow $13.1B (FCF margin 22.6%). Revenue growth 8.9%, Gross margin 65.0%, ROIC 13.7%, and 1Y Return 29.5% provide networking stability. Intrinsic value $84.3 and Total Debt to Equity 59.9% support defensive tech analysis.
Key Catalysts
- Steady 1Y Return 29.5% in enterprise tech
- Solid Free Cash Flow $13.1B with 22.6% margin
- Gross margin 65.0% for profitability
- ROIC 13.7% in mature operations
Risk Factors
- Modest Revenue growth 8.9% amid competition
- Total Debt to Equity 59.9% leverage
- Slower growth in legacy hardware
Stock #7: International Business Machines Corporation (IBM)
| Metric | Value |
|---|---|
| Market Cap | $271.9B |
| Quality Rating | 6.5 |
| Intrinsic Value | $204.5 |
| 1Y Return | 33.4% |
| Revenue | $65.4B |
| Free Cash Flow | $13.0B |
| Revenue Growth | 4.5% |
| FCF margin | 19.9% |
| Gross margin | 58.2% |
| ROIC | 9.6% |
| Total Debt to Equity | 237.8% |
Investment Thesis
International Business Machines Corporation (IBM), Market Cap $271.9B, Quality rating 6.5, shows Revenue $65.4B and Free Cash Flow $13.0B (FCF margin 19.9%). Revenue growth 4.5%, Gross margin 58.2%, ROIC 9.6%, and 1Y Return 33.4% reflect hybrid cloud progress. Intrinsic value $204.5 amid Total Debt to Equity 237.8% offers turnaround value.
Key Catalysts
- 1Y Return 33.4% from AI and cloud shifts
- Reliable Free Cash Flow $13.0B
- Improving ROIC 9.6% in services
- Large-scale Revenue base $65.4B
Risk Factors
- High Total Debt to Equity 237.8%
- Low Revenue growth 4.5%
- Legacy business drag on margins
Stock #8: Novartis AG (NVS)
| Metric | Value |
|---|---|
| Market Cap | $265.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $146.5 |
| 1Y Return | 42.6% |
| Revenue | $55.5B |
| Free Cash Flow | $11.3B |
| Revenue Growth | 12.5% |
| FCF margin | 20.4% |
| Gross margin | 37.2% |
| ROIC | 19.1% |
| Total Debt to Equity | 71.6% |
Investment Thesis
Novartis AG (NVS), Market Cap $265.6B, Quality rating 6.1, generates Revenue $55.5B and Free Cash Flow $11.3B (FCF margin 20.4%). Revenue growth 12.5%, ROIC 19.1%, Gross margin 37.2%, and top 1Y Return 42.6% shine in global pharma. Intrinsic value $146.5 with Total Debt to Equity 71.6% for balanced analysis.
Key Catalysts
- Leading 1Y Return 42.6%
- Revenue growth 12.5% in innovative drugs
- Strong ROIC 19.1%
- Steady Free Cash Flow $11.3B
Risk Factors
- Lower Gross margin 37.2%
- Quality rating 6.1 trails peers
- Currency and regulatory exposures
Stock #9: Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $264.7B |
| Quality Rating | 7.3 |
| Intrinsic Value | $115.6 |
| 1Y Return | 7.3% |
| Revenue | $64.2B |
| Free Cash Flow | $13.0B |
| Revenue Growth | 1.7% |
| FCF margin | 20.3% |
| Gross margin | 82.8% |
| ROIC | 30.1% |
| Total Debt to Equity | 79.8% |
Investment Thesis
Merck & Co., Inc. (MRK) has Market Cap $264.7B, Quality rating 7.3, Revenue $64.2B, and Free Cash Flow $13.0B (FCF margin 20.3%). Gross margin 82.8%, ROIC 30.1%, but modest Revenue growth 1.7% and 1Y Return 7.3%. Intrinsic value $115.6 and Total Debt to Equity 79.8% highlight defensive pharma value.
Key Catalysts
- Exceptional Gross margin 82.8%
- High ROIC 30.1% efficiency
- Strong Free Cash Flow $13.0B
- Stable large Revenue base
Risk Factors
- Low Revenue growth 1.7%
- Weaker 1Y Return 7.3%
- Pipeline dependency risks
Stock #10: Philip Morris International Inc. (PM)
| Metric | Value |
|---|---|
| Market Cap | $249.9B |
| Quality Rating | 6.9 |
| Intrinsic Value | $161.7 |
| 1Y Return | 32.4% |
| Revenue | $39.9B |
| Free Cash Flow | $10.1B |
| Revenue Growth | 7.5% |
| FCF margin | 25.3% |
| Gross margin | 66.3% |
| ROIC | 25.0% |
| Total Debt to Equity | (557.5%) |
Investment Thesis
Philip Morris International Inc. (PM), Market Cap $249.9B, Quality rating 6.9, delivers Revenue $39.9B and Free Cash Flow $10.1B (FCF margin 25.3%). Revenue growth 7.5%, Gross margin 66.3%, ROIC 25.0%, and 1Y Return 32.4% support consumer staples resilience. Intrinsic value $161.7 despite Total Debt to Equity 557.5%.
Key Catalysts
- Solid 1Y Return 32.4%
- FCF margin 25.3% and ROIC 25.0%
- Consistent Revenue growth 7.5%
- Defensive Gross margin 66.3%
Risk Factors
- Negative Total Debt to Equity 557.5%
- Regulatory pressures in tobacco transition
- Sector-specific consumption risks
Portfolio Diversification Insights
This stock watchlist balances tech heavyweights (NVDA, MU, ORCL, CSCO, IBM ~50% allocation) with healthcare/pharma (LLY, ABBV, NVS, MRK ~40%) and consumer staples (PM ~10%). High-growth tech like NVDA (161.5% ROIC) complements stable pharma margins (e.g., LLY 83.0%), reducing sector risk. Cross-references show MU's 261.0% 1Y return pairing with ABBV's cash flow for volatility hedge, while low-debt NVDA offsets leveraged names like ORCL.
Market Timing & Entry Strategies
Consider positions during tech pullbacks for NVDA/MU or pharma dips post-earnings for LLY/ABBV, targeting intrinsic value gaps (e.g., MU at $435.3). Scale in on 1Y return momentum like NVS 42.6%, using ValueSense screeners for ROIC >20% confirmation. Monitor FCF trends quarterly for sustained entry.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These top 10 stock picks were curated via ValueSense criteria emphasizing Quality rating, intrinsic value, high ROIC, revenue growth, and Free Cash Flow, focusing on undervalued opportunities across tech and healthcare.
What's the best stock from this list?
Micron (MU) leads with 8.2 Quality rating, 261.0% 1Y Return, and $435.3 intrinsic value, though NVDA's 161.5% ROIC makes it a close contender for growth analysis.
Should I buy all these stocks or diversify?
Diversify across sectors like tech (NVDA, MU) and pharma (LLY, MRK) to balance high-growth (45.4% revenue) with stability (e.g., PM's 25.3% FCF margin), avoiding over-concentration.
What are the biggest risks with these picks?
Key concerns include high debt (ORCL 408.4%, ABBV -2,645.0%), negative FCF (ORCL -$13.2B), and sector cycles in tech/pharma, per ValueSense metrics.
When is the best time to invest in these stocks?
Target entries near intrinsic value levels (e.g., NVDA $75.6) during market corrections or positive earnings, using 1Y returns like MU's 261.0% for momentum timing.